Halo Labs is revolutionizing biopharmaceutical drug product quality by commercializing low volume, high throughput tools to characterize product stability and safety. From developability assessment through quality control, Halo Labs provides unprecedented insights that reduce development time and improve patient safety.
Halo’s management team is a seasoned group of life science professionals who on average have over 20 years of experience delivering solutions to the life science marketplace. Our growth strategy includes disrupting outdated analytical methods as well as addressing the challenges of the fastest growing biopharmaceutical sectors.
Our venture support comes from Agilent Technologies, Research Corporation Technologies (RCT), BioAdvance, Broad Oak Capital Partners, and Ben Franklin Technology Partners.